#United States #San Francisco #Securities Fraud #Hagens Berman #GeneDx Holdings

GeneDx Holdings Corp. Faces Legal Trouble Over Securities Fraud

On July 31, 2026, Hagens Berman Sobol Shapiro LLP announced that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) concerning claims of securities fraud. This news comes as a significant development for investors who may have experienced notable losses due to what the firm alleges were misleading statements made by GeneDx's management regarding the company's performance and prospects.

Overview of the Class Action Lawsuit

The class action pertains to the period between April 16, 2025, and May 4, 2026. During this timeframe, GeneDx is accused of providing investors with a skewed vision of its technological capabilities and the strategic advantages of its acquisition of Fabric Genomics. The law firm is currently encouraging anyone who believes they have been impacted by this situation to reach out, especially prior to the lead plaintiff deadline set for August 3, 2026.

Key Allegations Against GeneDx

The lawsuit centers on allegations that GeneDx made false and misleading representations about the synergy between it and Fabric Genomics. Specifically, the company is said to have exaggerated the benefits of Fabric as a driver of revenue growth and lowered operational costs. Instead of a seamless integration, GeneDx reportedly faced significant internal challenges, which the management allegedly concealed from investors.

Understanding the Financial Impact

The gravity of these claims came to light after GeneDx announced disappointing financial results for the first quarter of 2026. The report highlighted several distressing outcomes:

• - Revenue Shortfalls: The company missed revenue expectations substantially for its exome and genome testing divisions.
• - Decreased Margins: Reported adjusted gross margins fell from 74% to 69%, raising concerns about profitability.
• - Guidance Revision: Full-year revenue forecasts were slashed dramatically, lowering projections to a range of $475 million to $490 million.
• - Impairment Charges: A staggering impairment loss of $31.2 million was attributed to the Fabric acquisition, erasing roughly 94% of the cash initially paid for this division.

The immediate aftermath of these disclosures was a catastrophic response from the stock market, as GeneDx’s share prices plummeted nearly 49.2% in a single trading session—from $67.93 to $34.51—leading to billions in losses for shareholders.

Hagens Berman's Investigative Actions

According to Reed Kathrein, a partner at Hagens Berman, these alleged misrepresentations have serious implications for the integrity of the company and its executives. The firm is currently analyzing the extent of the misleading statements made regarding Fabric Genomics’ integration and its alleged AI-driven efficiencies.

What Affected Investors Can Do

Investors who purchased shares of GeneDx between April 16, 2025, and May 4, 2026, and who have since incurred substantial losses are urged to contact Hagens Berman. Stakeholders have until August 3, 2026, to petition for lead plaintiff status in court. Those with additional information that might aid the investigation are also encouraged to step forward.

For whistleblowers with insider knowledge, there are opportunities to participate in the investigation while potentially qualifying for rewards through the SEC Whistleblower program.

Conclusion

Against the backdrop of GeneDx's troubling disclosures and significant stock slump, investors are advised to remain vigilant and informed. Hagens Berman is dedicated to holding corporate entities accountable and ensuring justice for those impacted by negligent actions in the market. For continuous updates on this case and related news, stay connected with Hagens Berman on their social media or through their website.

For more details on the class action or how to participate, please visit Hagens Berman's official website or contact them directly at 844-916-0895.

This ongoing case underscores the essential need for transparency and truthfulness in corporate communication—a reminder to both current and prospective investors of the inherent risks in the financial markets.